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Abstract
Background: Cervical cancer (CC) is -second to breast cancer- a dominant cause of gynecological cancer-related
deaths worldwide. CC tumor biopsies and blood samples are of easy access and vital for the development of future
precision medicine strategies.
Design: BIO-RAIDs is a prospective multicenter European study, presently recruiting patients in 6 EU countries.
Tumor and liquid biopsies from patients with previously non-treated cervical cancer (stages IB2-IV) are collected at
defined time points. Patients receive standard primary treatment according to the stage of their disease. 700
patients are planned to be enrolled. The main objectives are the discovery of -dominant molecular alterations,
-signalling pathway activation, and -tumor micro-environment patterns that may predict response or resistance to
treatment. An exhaustive molecular analysis is performed using 1° Next generation sequencing, 2° Reverse phase
protein arrays and 3° Immuno-histochemistry.
Discussion: The clinical study BIO-RAIDs is activated in all planned countries, 170 patients have been recruited till now.
This study will make an important contribution towards precision medicine treatments in cervical cancer. The results
will support the development of clinical practice guidelines for cervical cancer patients to improve their prognosis and
their quality of life.
Trial registration: Clinicaltrials.gov: NCT02428842, registered 10 February 2015.
Keywords: Prospective European biobanking study, Precision medicine, Molecular profiling, Cervical cancer, Next
generation sequencing, Reverse phase protein array, Tumor micro environment, Targeted therapy, Patient stratification,
International trial, Clinical trial operations, Quality control of pelvic radiotherapy, Biobanking, HPV typing
Background
Cervical cancer (CC) is the second cause of gynecological
cancer-related deaths worldwide [1]. Incidence and mor-
tality rates of CC are up to twelve times higher in Eastern
Europe as compared to North/Western Europe due to
previously inadequate or absent screening practices [1, 2].
HPV is commonly accepted as the major etiological
cause of CC [3]. Preventive vaccination is expected to
impact incidence rates in more than 20 years from now
when the first vaccinated adolescents will reach the age
of peak incidence (35–50) of CC. In the meantime,
women are at risk and there is an unmet medical need
to improve the diagnosis and treatment of CC.
Diagnosis, standard treatment and prognosis of CC
FIGO (International Federation of Gynecology and
Obstetrics) classification for CC was revised in 2009.
The use of MRI imaging was encouraged towards im-
proving staging accuracy (92 %) [4–7]. While screen-
ing has decreased the incidence of CC in Western EU
countries, its treatment has not changed over the last
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15 years, the most recent improvement being the associ-
ation of radio-chemotherapy [8, 9]. Addition of Bevacizu-
mab [10] or Gemcitabine [11] to chemotherapy did show
small improvements, but these treatments are costly,
have side effects and are not available in many countries
in need.
In early stage disease (≤IB1) and in a subset of patients
of stage IB2-IIA, a surgical approach may cure the
patient [12–15]. For stages IB2 to III, concurrent
chemo-radiation with a platinum-based reagent is the
recommended standard of therapy [9]. Unfortunately,
advanced stage (III-IV) disease remains a significant
public health problem [16]. In on-going clinical trials,
the impact of additional chemotherapy either as neo-
adjuvant (INTERLACE trial [17] or adjuvant (OUTBACK
trial: ASCO meeting 2012) strategies, are currently being
assessed.
Precision medicine in CC and BIO-RAIDs objectives
Molecularly targeted agents in CC are still being tested
in clinical trials. CC patients may have variable out-
comes and specific genetic mutations have already been
shown to impact clinical response to standard therapy
by us [18] and others [19–21]. The Cetuxicol trial, a
phase 2 trial sponsored by Institut Curie, showed that
the addition of Cetuximab over a 6 week period, did not
improve DFS. Of interest was the finding that PI3K
pathway tumor mutations in the Cetuximab treatment
arm led to a worse outcome (De la Rochefordiere 2015).
We are presently lacking prognostic and predictive bio-
markers for CC treatment and there is a growing need
for the development of these to follow up the course of
the disease. Due to the multiplicity of potential genetic
alterations, retrospective molecular assessments in small
patient populations are mostly inconclusive. For these
reasons, we initiated BIO-RAIDs, a prospective study
with extensive biobanking which aims to identify predict-
ive biomarkers for treatment response of cervical cancers
in both Western and Eastern European countries. To our
knowledge, BIO-RAIDs is the first large prospective trial
of this type in the field of CC. At the medical/scientific
level, BIO-RAIDs will be crucial in setting the ground for
future precision medicine studies by identifying a set of
stratification criteria for cervical carcinomas as well as
other cancers with similar molecular alterations.
Methods
The BIO-RAIDs study is at the core of the European
project called RAIDs “Rational molecular Assessment
Innovative Drug selection” coordinated by Institut
Curie. RAIDs is based on an international multidis-
ciplinary cooperation between academic hospitals,
SMEs and platforms for translational research
www.raids-fp7.eu/ (Fig. 1).
Institut Curie (France) is responsible for the overall
coordination and management (study documents and
data quality, statistical analyses). In countries other than
France, the registration, management, and monitoring of
clinical centers is delegated to a national coordinator.
Study design and objectives
BIO-RAIDs is a prospective European study, involving
oncology centers from France, Germany, Serbia, the
Netherlands, Romania and Moldova. 700 patients with
previously untreated, advanced stage CC (stage IB2-IV)
will be enrolled. The recommendations for standards of
treatment by stage of disease as well as the timing of
biopsies are shown in Fig. 2. The primary objective of
the study is to assess dominant mutations and activation
of signaling pathways in cervical cancers predictive of re-
sponse to standard treatment. Secondary objectives of the
study are: 1. The determination of PFS at 18 months as a
function of dominant genetic or protein alterations; 2. The
descriptive analysis of standard treatments applied in
participating European countries; 3. A descriptive ana-
lysis of grade 3 and 4 side effects; 4. A descriptive
analysis of the frequency of molecular alterations ac-
cording to geographic location.
Ethical considerations and regulatory approvals
Approval for the BIO-RAIDs study has been obtained
from ethics committees in all participating countries
(Comité pour la protection des personnes (CPP) Ile de
France in France, The Serbian Medical Society Belgrade
in Serbia, The Protocol Toetsingscommissie of the
Antoni van Leeuwenhoek (PTC) in the Netherlands, The
Medizinische Hochschule Hannover Ethik-kommission
in Germany, The National Ethics Committee of Health
Ministry of Republic of Moldova, Academy of Medical
Sciences National Ethics Committee for medicines and
medical devices in Romania). BIO-RAIDs is conducted
in accordance with the guidelines of the Declaration
of Helsinki, and the principles of Good Clinical Prac-
tice as defined by the International Conference on
Harmonization (ICH-E6, 17/07/96) as well as specific
laws and regulations of the countries were the study is
performed. Centers participating in BIO-RAIDs study are
listed in the Table 1.
Patient recruitment, data collection and biobanking
Eligible patients with stage IB2-IV disease, scheduled for
primary surgery, chemo-radiation or primary chemother-
apy are invited to participate in this study. Table 2 details
the inclusion and exclusion criteria. Documented informed
consent is obtained for all patients. Patient data is anon-
ymized and recorded in an electronic Case Report Form
(eCRF) (Quanticsoft). The eCRF generates patient specific
unique barcode numbers for each sample. At study entry,
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baseline demographic characteristics, medical history and
findings of staging such as complete physical and
gynecological examination, abdominal and pelvic CT, pel-
vic MRI (+/- optional PET-CT) are recorded. A central re-
view of MRI imaging is planned to be performed in Serbia.
Biobanking: sample collection and procedures
Tumor and serum samples are collected at defined time
points as shown in Table 3 and stored at −80 °C (muta-
tional data) or at room T° in case of preparation of fixed
paraffin embedded sections (IHC). Standard operating
procedures have been established by the RAIDs consor-
tium for biopsy handling as well as for blood and sera
collections. All samples are centralized in the RAIDs
biobank located in Morahollum (SeQomics, Hungary).
Tumor samples
One biopsy composed of at least 3 tumor samples must
be collected at baseline before any treatment. In the case
of large cervical lesions, 2 additional tumor samples may
Fig. 1 RAIDs project - participant countries. RAIDs is an international multidisciplinary cooperation between academic hospitals, SMEs and
platforms for translational research (http://www.raids-fp7.eu/). 7 EU countries participate in RAIDs project: France, Hungary, Germany, Netherlands,
Serbia, Moldova and Romania. BIO-RAIDs study is performed in 6 EU countries: France, Germany, Netherlands, Serbia, Moldova and Romania
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be collected: 1 tumor sample will be paraffin-embedded
(FFPE) for Immunohistochemistry analysis and 2 to 4
tumor samples will be instantly frozen in liquid nitrogen
and stored at −80 °C. The minimum size for tumor sam-
ple is 0.3 cm3 (bite of 7*3*1.5 mm). The ideal size is
however > 0.3 cm3, and preferably 0.5–1 cm3. In case of
poor response during the primary treatment sequence
(at the insertion of the brachytherapy device which is
done under general anesthesia following radio chemo-
therapy or at in case of surgery), 2 additional tumor
samples may be collected and instantly frozen in liquid
nitrogen and stored at −80 °C. At the end of the patient’s
primary treatment sequence and in case of accessible re-
sidual/recurrent disease, 2 residual tumor samples will
be collected and instantly frozen in liquid nitrogen and
stored at −80 °C.
Fig. 2 Recommended treatment and time of biopsies. Patients with previously untreated, advanced stage cervical cancer (stage IB2-IV) will be
enrolled in BIO-RAIDs study and undergo standard treatment. The recommendations for standards of treatment by stage and the timing
of biopsies are shown. B1: biopsy before treatment; B2: biopsy during or at the end of treatment in case of poor response/progression;
B3: biopsy in case of recurrence
Table 1 Centers participating in the BIO-RAIDs study. All the participating centers in the BIO-RAIDs study on the moment of
submission are shown
France Institut Curie - Paris, Institut Bergonie - Bordeaux, Institut Rene Huguenin Curie - Saint Cloud, Institut Gustave Roussy –
Villejuif, Institut de Cancérologie Lorraine – Nancy, Centre Georges François Leclerc – Dijon ; Institut de Cancérologie
de l'Ouest - Nantes ; Institut de Cancérologie de l'Ouest - Paul Papin – Angers ; Hôpital Européen Georges Pompidou -
Paris; Institut régional du Cancer Montpellier (Val d'Aurelle) – Montpellier and Centre Antoine Lacassagne-Nice.
Germany Hannover Medical School – Hannover, Carl-Gustav Carus University - Dresden
The Netherlands Netherlands Cancer Institute – Antoni van Leeuwenhoek (NKI-AVL) - Amsterdam, Amsterdam Medical Center - Amsterdam
Romania Clinica Radiotherapie Timisoara, Spitalul Clinic Municipal – Oradea, Institutul Regional de Oncologie - Iasi
Serbia Institut of Oncology of Vojvodina (IOV) – Novi Sad
Moldova Institute of Oncology of Republic of Moldova - Chisinau
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Blood sampling
Before treatment, 7 mL of blood is collected in EDTA
tubes for DNA extraction and sequencing at Seqomics
and 10 mL of blood collected in adapted tubes for serum
preparation. At the end of treatment and during follow-
up visits at 6 and 12 months 10 mL of blood will be col-
lected in adapted tubes for serum preparation. Sera will
be stored at −80 °C and centralized at Seqomics.
Sample labelling
Each sample (tumor, blood or serum) is meticulously la-
beled with a unique 2D barcode provided by Institut
Curie at the beginning of the study. For each label a pa-
tient specific kit number is assigned by the electronic
CRF software at the time of patient inclusion.
Molecular profiling is performed as summarized in
Fig. 3. Raw data of molecular profiling together with
the clinical data of patients are integrated into a com-
mon repository (KDI: Knowledge and Data Integra-
tion) (Fig. 4), developed by Institut Curie and already
successfully used for the European project MAARS -
(261366) as well as for the SHIVA clinical trial at
Institut Curie [22].
Clinical follow-up
Early clinical follow up may vary according to the
chosen treatment strategy and a function of the FIGO
stage of the disease. Detailed clinical and imaging evalu-
ations are carried out at the end of treatment and at 6,
12 and 18 months. All clinical, sampling and imaging
data are registered in the eCRF.
Quality control for radiotherapy
Standardization for External Beam Radio-chemotherapy
(EBRT) and Brachytherapy (BT) delineation in partici-
pating centers was improved through online workshops
(ODW) according to the GEC-ESTRO recommendations
[23] and the EMBRACE protocol (An International
study on MRI-guided Brachytherapy in locally advanced
CC: EMBRACE. https://www.embracestudy.dk/). Centers
with deviations from the treatment protocol are being
offered an on-site training period in a reference center.
Contour evaluation methodology: Intraobserver vari-
ability between 3 contouring periods: 1. Quantitative
differences: DICE index. 2. Qualitative assessment: target
Volumes, areas contoured. Organs at Risk A: Optimal: >
0.81; B: Suboptimal: < = 0.81 (Breunig et al. IJROB 2012)
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1) No prior treatment for CC. 1) Patient enrolled in a clinical trial involving an investigative new agent.
2) FIGO Stage IB2 to IVB; all histological subtypes
(excluding neuro-endocrine type).
2) Co morbidity, preventing patient to tolerate the proposed standard treatment.
3) Past history of invasive cancer over the 5 years preceding entry in the present trial
(except basal cell carcinoma and carcinoma in situ of the cervix).3) Pelvic MRI available or planned before the start of
treatment.
4) Possibility to communicate imaging data by CD
ROM (format DICOM 3.0 or more).
4) Impossibility to carry out evaluation by MRI (patient claustrophobic, pacemaker, metallic
implant, non-availability, other).
5) Patient deprived from ability to decide on her own.5) Disease amenable to biopsy (3 tumor samples are
mandatory prior to treatment).
6) Patient unable to have a regular follow up for geographical, social or psychological reasons.
6) Age ≥ 18 years.
7) Pregnancy or patient old enough to procreate and not using effective contraceptive
method.2) ECOG 0-2.
3) Life expectancy > 6 months.
4) Patient eligible for standard treatment (according to
standards of each center).
5) Patient having health care insurance.
6) Informed and signed consent by patient.
Table 3 Biobanking during BIO-RAIDs study
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A: Optimal: > 0.81 Target Vol. B: Average: 0.65 – 0.81 C:
Suboptimal: < 0.65 (Dimopoulos et al. Radioth Oncol 2009;
Petersen et al. IJROB 2007) Initial analyses demonstrated
interobserver variability for baseline contouring. Quantita-
tive analyses were performed between centers and years of
experience. Qualitative analyses compared group contours
with reference contours. ANOVA was applied for analysis
based on DICE, the significance of: institution; organ at risk
(OAR) versus target volume (TV); organ; participant’s years
of experience (grouped in 2 levels: Residents vs. Specialists).
As an example of results of contouring workshop: most
centers have an average DICE index for each volume be-
tween 0.65 and 0.81. This loosely falls within the average
(B) category. If the participants improve in the guideline
and final contouring sessions, these centers are initially
prepared to participate within the RAIDs study, and
only would need to complete a dummy run to validate
the dosimetry as well. Half of the RAIDs institutions
have suboptimal (C) DICE indexes for the GTV-node
volume. The qualitative analyses showed some concep-
tual errors: 1. delineating vessels or clinical nodal target
volumes instead of the actual macroscopic lymph
nodes. 2. these results are partly due to the clinical case
itself: 1. paraaortic lymph node which on the computed
tomography image set for contouring seemed enlarged,
although the clinical information explicitly stated that
no paraaortic lymph nodes were pathological. 2. suspi-
cious lymph node in the left groin, which within the
live sessions was deemed as inflammatory by an experi-
enced radiotherapist.
Acute or delayed toxicities of treatment will be docu-
mented in the eCRF.
Bioinformatics and statistical analysis
We try to assess which are the dominant mutations and
which signaling pathways are activated in cervical can-
cers based on potentially deleterious genomic or prote-
omic alterations (COSMIC database). Furthermore we
want to ascertain which abnormalities will be predictive
of response to standard treatment and outcome. Ana-
lysis of a large number of patients is necessary because if
a specific driver mutation is present in only 7 % of pa-
tients, 700 patients need to be evaluated to detect this
mutation in 50 patients. No statistical hypothesis applies,
but appropriate statistical methods will be used to
analyze the results.
1. Definitions:
Complete response (CR) is assessed by MRI at the end
of treatment (latest at 6 months) based on RECIST cri-
teria. In the case of surgery, complete response will be
Fig. 3 From sample to technique – sample flow. Patient samples (blood samples and biopsies) will be centralized at local centers and then sent
to research platforms, where the material will processed and analyzed by different methods ( IHC, HPV insertion, sequencing, RPPA). Centralized
biobanking of remaining material will be performed at SeqOmics (Hungary)
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defined as a pathological complete response. Progression-
free survival (PFS) is defined as the time from diagnosis to
the date of the first progression or death. If patients are
alive and free of progression, they will be censored and
their PFS will be defined as the time from diagnosis to the
date of last known follow-up visit. Overall survival (S) will
be defined as the time from diagnosis to the date of death
or last follow-up. Survival rates will be estimated using
the Kaplan-Meier method. PFS and OS will be com-
pared to molecular phenotypes or clinical factors using
the log-rank test.
2. Statistical methodology
Univariate and multivariate analyses will be performed
to evaluate the association between each set of bio-
markers (gain or loss of function) and clinical outcome.
If the outcome measure is CR, a logistic regression is
used. If the outcome measure is PFS or OS, a Cox re-
gression model is preferred using 95 % confidence inter-
vals. Multivariate analyses will take into account
correlations between the different factors allowing to de-
fine a genomic or proteomic “response signature”, cap-
able to predict the different outcome measures as
compared to the presently available criteria. The level of
significance is fixed at 5 %. Corrections for multiple test-
ing to correct for the occurrence of false positives will
be by the Benjamini-Hochberg method. Stratification ac-
cording to geographical location will take into account
the heterogeneity of standard treatment. Analyses will be
performed using R° software by the Biostatistics Depart-
ment of Institut Curie.
3. Bioinformatics
The bioinformatics’ platform at Institut Curie together
with SeQomics (Hungary) will ensure reliable down-
stream bioinformatics analysis of patient samples. The
tumors will be characterized by a list of features such as:
mutations, structural variants, protein expression +/-
phosphorylation, and presence of an immune signature
by IHC among others. In an unsupervised analysis, an
exhaustive exploration of the molecular profiles, without
an a priori model will be carried out to characterize the
dominant molecular abnormalities. This approach will
involve a principal component analysis, an independent
component analysis as well as clustering. This explora-
tory analysis is meant to detect possible biases due to
technological aspects or sample handling (batch effect).
The supervised analysis will attempt to identify and
Fig. 4 KDI – Knowledge and Data Integration. Integration of heterogeneous clinical and biological/molecular data requires a powerful
information system. Data integration: all data (clinical data from eCRF, biological data, including tumor microenvironment (TME) analysis using
immunohistochemistry (IHC) and HPV typing and raw data from technological platforms: exome and targeted sequencing on gDNA and ctDNA,
reverse phase protein analysis (RPPA)) will be integrated into KDI core system. Afterwards advanced research functionalities will enable multiple
data queries. Specific bioinformatics pipelines will generate new integrative knowledge from these heterogeneous sources of data (figure adapted
from Servant et al. [22])
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validate biomarkers using machine learning techniques
such as LASSO, ridge regression, elastic net or SVM. The
prediction of the influence of specific molecular abnor-
malities on patient outcome needs to be validated by their
impact on the major endpoints which have been defined
above: 1° Complete Response (CR). 2° Progression-free
survival (PFS); 3° Overall survival (OS). Finally, results of
both the unsupervised and supervised analyses will be
compared to published classifications.
4. Biomarkers identification
The biomarkers identified in the second step will be
integrated with well-known clinical (FIGO stage, node
involvement etc.) and histological prognostic factors in a
multivariate model as defined in the first step. Our ob-
jectives are to study correlations and prioritize markers
for their distinctive ability to predict complete response,
progression free survival and overall survival.
Discussion
BIO-RAIDs is one of the first prospective studies includ-
ing a substantial biobanking effort for molecular profiling
using fresh frozen tumor material with high standards of
quality control of both biological samples and clinical
data. While the aim of this study is to assess the relevant
impact of dominant genetic/proteomic or immune param-
eters on primary treatment outcome in a prospective well
controlled patient population with sufficient numbers to
draw valid conclusions, there were a number of shortcom-
ings in the initiation phase of this trial.
The clinical study BIO-RAIDs is now activated in all
planned countries -up to two years after the start of the
EU project- and patient recruitment numbers are satis-
factory. Multiple bottlenecks causing the delay in this
international study initiation were identified. Significant
delays in the provisional time frame guidelines were
caused by 1° Regulatory aspects; 2° Insurance modalities;
3° Negotiation of sponsorship delegation contracts; 4°
Site specific logistics for biobanking; 5° Clinical trials op-
erational management. Based on our experience, we be-
lieve there is a real need to develop procedures that
facilitate the implementation of trials with biobanking in
the era of precision medicine.
Conclusion and perspectives
The present protocol may serve to model the relation-
ship of molecular aberrations to outcome in cervical
cancer. Moreover this may apply to other cancers as
well, since treatment response and outcome of a variety
of cancers does not segregate according to histological
tumor type. Response to treatment may in fact be more
closely related to molecular driver genes than to tumor
histotype. The implication of this project for the clinical
practice of the future is to stratify cancer patients for the
most appropriate treatment option.
Knowing the relative risk of good or bad outcome of
specific tumor deregulations will be instrumental in guid-
ing us towards more specific and less toxic treatments
while also allowing the right amount of supervision and
treatment, appropriate for each patient. In the RAIDs pro-
ject, 20 cell lines have been collected and have been ana-
lyzed for molecular markers and for treatment response to
a large panel of drug combinations. These may serve as
companion diagnostics tools in the future.
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